



## **Maggie Shafmaster, Ph.D., J.D.**

Maggie Shafmaster is an independent intellectual property consultant to the biotech and pharma industries. For almost 30 years, she has provided legal and strategic advice to her science and business clients related to interactions with third parties, IP portfolio development and potential and ongoing patent disputes in the U.S. and the EU.

Prior to becoming a consultant, Dr. Shafmaster was Vice President and Chief Patent Counsel at Sanofi Pasteur, the vaccine arm of global healthcare corporation Sanofi. Until its acquisition by Sanofi, Dr. Shafmaster was Senior Vice President and Chief Patent Counsel for

Genzyme Corporation, a global biotechnology company specializing in rare and ultra-orphan diseases and utilizing a variety of technologies including cell and gene therapies.

Dr. Shafmaster's background includes both science and law. She received her B.A. in Biology from the University of California, her Ph.D. in Molecular Biology & Virology from Cornell University and engaged in Post-Doctoral Research in the Department of Biochemistry and Molecular Biology at Harvard University. She received her law degree from New York Law School, where she graduated summa cum laude.

Dr. Shafmaster also represented Genzyme's interests in industry trade organizations, worked with its government relations office on pending legislation impacting the industry, and has been an invited speaker on a variety of topics relating to biologics and biosimilar drug products. Biologics are products made in living cells, including therapeutic proteins such as antibodies, and cell and gene therapy products. Biosimilars are "generic" versions of biologics that have an abbreviated approval pathway based on utilization of data generated by an innovator company.